Gleamer Cements Market Leadership with Strategic Acquisition of MRI AI Innovators Pixyl and Caerus Medical, Creating the Most Comprehensive Proprietary AI Imaging Portfolio

PARIS, FR – 11th March 2025

Gleamer, leading company in AI medical imaging, today announces that it acquires Pixyl, a pioneer in FDA- and CE-cleared Neuro MRI applications, and Caerus Medical, developer of cutting-edge Lumbar MRI AI solutions. These strategic acquisitions position Gleamer as the only AI provider with an unmatched, proprietary suite of solutions covering all core imaging modalities—X-ray, Mammography, CT, and now, MRI—further solidifying its leadership in the radiology AI market.

With its robust portfolio, Gleamer is redefining the future of AI-powered radiology, providing radiologists with best-in-class tools that optimize efficiency, enhance diagnostic accuracy, and accelerate patient care. This latest expansion ensures that Gleamer remains the first choice for institutions seeking comprehensive AI integration across their imaging workflows.

“With the addition of Pixyl and Caerus Medical, Gleamer now offers the most extensive proprietary AI-driven imaging portfolio in the industry. This move marks a transformative leap forward, empowering radiologists with cutting-edge MRI applications while strengthening our leadership in medical imaging AI,” said Christian Allouche, CEO & co-founder of Gleamer. “These acquisitions underscore our unwavering commitment to revolutionizing radiology, accelerating the adoption of AI, and delivering superior diagnostic precision.”

Pixyl, an award-winning innovator in brain MRI analysis, is recognized for its flagship product Pixyl.Neuro, which has already gained significant traction. The software enables the early detection of neuroinflammatory and neurodegenerative conditions, including Alzheimer’s disease, unlocking life-changing opportunities for early intervention. With new reimbursement pathways emerging in the U.S., Pixyl’s solutions are poised for rapid adoption, reinforcing its role at the forefront of AI-driven radiology innovation. “Joining Gleamer amplifies the impact of our technology, bringing our breakthrough MRI applications to a global audience,” said Senan Doyle, CEO of Pixyl. “Together, we are setting new standards in AI-powered radiology and driving the future of neuroimaging.”

Caerus Medical’s AI technology revolutionizes lumbar spine MRI interpretation, offering unparalleled precision in detecting all relevant findings (disc herniation, stenosis, spondylolisthesis etc.). This comprehensive approach enhances workflow efficiency and diagnostic reliability, streamlining the reporting process for radiologists. “The Caerus Medical team is thrilled to become part of Gleamer, the leader in AI-powered radiology,” said David Vittecoq, CEO of Caerus Medical. “This collaboration will fast-track the deployment of our lumbar MRI application and drive groundbreaking advancements in musculoskeletal imaging.”

With these acquisitions, Gleamer’s global workforce surpasses 100 employees across seven countries, bolstering its MRI research and development efforts. The integration of Pixyl and Caerus Medical within Gleamer’s AI Factory will accelerate innovation, ensuring the rapid deployment of next-generation imaging solutions that meet the evolving needs of modern radiology.

About Gleamer

Founded in 2017, Gleamer considers AI to be a key solution for addressing the sharp rise in demand for medical imaging, stemming from the challenges of an ageing population, the increasing prevalence of chronic diseases, and the problems of access to healthcare. The company's suite of AI-powered solutions, across X-Ray, Mammography, CT and now, MRI, supports radiologists and clinicians in their diagnoses, thereby improving reliability and reducing the time taken to read and process examinations. The relevance and exceptional performance of these solutions have been recognised worldwide thanks to 30 publications in highly regarded peer-reviewed journals. With 35 million exams analysed across over 2,000 institutions, spanning 45 countries across all continents, Gleamer’s solutions are now widely acclaimed within the medical imaging industry. www.gleamer.ai

About Caerus Medical

Founded in 2020, Caerus Medical is a Paris-based AI company specializing in musculoskeletal MRI analysis to enhance patient care pathways. Their first product, LumbarMR, utilizes artificial intelligence to detect lumbar disorders on MRI scans, supporting radiologists and physicians in improving the diagnosis. Caerus Medical is committed to advancing musculoskeletal care through innovative AI applications. ​​Their development and expertise have been led by David Vittecoq, the current CEO and have been financed and supported by France Imageries Territoires, their previous majority shareholder. www.caerusmedical.com

About Pixyl

Founded in 2015 as a spin-out of French labs Inria and Inserm, Pixyl is a pioneering medical technology company dedicated to transforming patient care by placing the most advanced AI directly in the hands of radiologists and clinicians. Their flagship solution, Pixyl.Neuro, leverages state-of-the-art artificial intelligence to detect subtle anomalies in brain MR images associated with neuroinflammatory and neurodegenerative disorders. Rigorously tested and validated, Pixyl.Neuro is both FDA-cleared and CE-marked as a Class IIa medical device, ensuring the highest standards of safety and efficacy. www.pixyl.ai